Bora Pharmaceuticals Acquires MacroGenics' GMP Facility: Taiwan CDMO Giant Expands US Biologics Footprint

May 14, 2026 — Bora Pharmaceuticals, a Taiwan-based global pharmaceutical manufacturer, has agreed to acquire MacroGenics' GMP drug substance manufacturing operations for $122.5 million, plus up to $5 million in contingent consideration tied to future customer orders. The deal gives Bora a fully operational FDA and PMDA-inspected biologics manufacturing facility in Rockville, Maryland — significantly expanding its capabilities in the high-growth biologics CDMO market.

The Rockville facility, which has operated as an outsourced manufacturing partner since 2022, is equipped with five 2,000-liter and two 500-liter single-use bioreactors, fully integrated QC and analytical laboratories, and a workforce of approximately 140 employees who will be retained by Bora. The site currently generates over half of its revenue from commercial-stage monoclonal antibody manufacturing, with the remainder from clinical-stage programs and a strong project pipeline.

Strategic Significance: Building an End-to-End Biologics Platform

The acquisition is a pivotal step in Bora's strategy to build an integrated end-to-end biologics CDMO platform. Combined with Tanvex Biopharma, which operates the Group's biologics CDMO franchise under the "Bora Biologics" brand, and Bora's existing sterile drug product capabilities, the Rockville site brings total drug substance capacity to 20,000 liters across single-use bioreactor systems.

"This acquisition marks a pivotal step in strengthening Bora's integrated biologics CDMO platform in the United States," said Bobby Sheng, Chairman and CEO of Bora Group. "Together with our sterile drug product capabilities, this is expected to scale the Group's end-to-end biologics platform, allowing customers to advance programs from development through commercial supply with one single partner."

The deal also includes a long-term CDMO service agreement with MacroGenics and assumes a substantial backlog of commercial-stage programs. For MacroGenics, the sale allows the clinical-stage biopharmaceutical company to refocus resources on its antibody-based oncology pipeline while maintaining manufacturing supply continuity through the service agreement.

The US Biologics CDMO Market: Convergence of Demand Drivers

The US biologics CDMO market is experiencing robust growth driven by several converging factors:

• ADC pipeline expansion: Antibody-drug conjugates (ADCs) represent the fastest-growing segment in oncology, with over 300 ADC programs in clinical development worldwide. ADC manufacturing requires specialized drug substance capabilities that are in short supply
• Biosimilar wave: The expiration of exclusivity for blockbuster biologics including Humira, Stelara, and Keytruda is driving a surge in biosimilar development, creating demand for large-scale biologics manufacturing capacity
• Cell therapy scaling: CAR-T and other cell therapies are transitioning from clinical to commercial manufacturing, requiring GMP infrastructure that many biotech companies lack internally
• Supply chain reshoring: Post-pandemic concerns about manufacturing concentration in specific geographies are driving demand for US-based biologics manufacturing capacity

Asia-Pacific CDMOs Penetrating the US Market

Bora's acquisition of the Rockville facility reflects a broader trend of Asia-Pacific CDMOs establishing US manufacturing footprints. This strategy addresses several market realities:

• Regulatory preference: US biotech companies increasingly prefer CDMOs with FDA-inspected US facilities for late-stage and commercial manufacturing
• Supply chain resilience: Customers demand manufacturing redundancy across geographies to mitigate disruption risk
• IP protection: US-based manufacturing provides stronger intellectual property protections for sensitive biologics programs
• Speed to market: Domestic manufacturing eliminates shipping delays and reduces cold-chain logistics complexity

Other Asia-Pacific CDMOs have pursued similar US expansion strategies, including Samsung Biologics' investments in US capacity and WuXi Biologics' facility expansions. Bora's acquisition of an existing, revenue-generating facility represents a faster path to market than greenfield construction, which typically requires 3-5 years from groundbreaking to first GMP production.

Implications for the Biologics Supply Chain

The Bora-MacroGenics transaction has several implications for B2B pharmaceutical suppliers and the broader biologics ecosystem:

• Raw material supply: Expanded biologics manufacturing capacity will drive increased demand for cell culture media, chromatography resins, single-use technologies, and filtration systems
• Analytical services: GMP manufacturing operations require extensive analytical support including potency assays, impurity characterization, and stability testing
• Fill-finish capacity: As drug substance capacity expands, downstream fill-finish services become the next bottleneck, creating opportunities for specialized fill-finish CDMOs
• Regulatory compliance: Multi-site operations across US and Asia-Pacific jurisdictions create demand for regulatory consulting and quality system harmonization services

Outlook: The Race for Biologics Manufacturing Scale

The global biologics CDMO market is projected to exceed $50 billion by 2030, driven by the expanding pipeline of monoclonal antibodies, ADCs, bispecifics, and cell therapies. Capacity remains the primary constraint, with leading CDMOs reporting utilization rates above 80% and wait times of 12-18 months for new client programs.

Bora's acquisition of the Rockville facility positions the company as a significant player in the US biologics CDMO market, with the scale and capabilities to compete for the most demanding commercial manufacturing programs. For API and raw material suppliers, the expansion of biologics manufacturing capacity — both through acquisitions like this one and through greenfield expansions — represents a sustained, multi-year growth opportunity across the entire biologics supply chain.